Starboard wants to hold Pfizer leadership 'accountable' for overpaid M&A deals, poor return on R&D investment

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.

Starboard has called on Pfizer’s board to “hold management accountable” for what the hedge fund described as poor revenue returns on investments in R&D and M&A, according to a new presentation (PDF) for the 13D Monitor Active-Passive Investor Summit in New York.